Ingo Winschel

Ingo Winschel

Auto-generated profile, based on publicly available information

Ingo Winschel

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2025 in Cell
Verified
Journal Article
Open access
MWMarcel S. Woo
Marcel S. Woo
JBJohannes Brand
Johannes Brand
LBLukas C. Bal
Lukas C. Bal
MMManuela Moritz
Manuela Moritz
MWMark Walkenhorst
Mark Walkenhorst
MFManuel A. Friese
Manuel A. Friese
Inflammation, aberrant proteostasis, and energy depletion are hallmarks of neurodegenerative diseases such as multiple sclerosis (MS). However, the interplay between inflammation, proteasomal dysfunction in neurons, and its consequences for neuronal integrity remains unclear. Using transcriptional, proteomic, and functional analyses of proteasomal subunits in inflamed neurons, we found that interferon-γ-mediated induction of the immunoproteasome subunit, proteasome 20S beta 8 (PSMB8) impairs the proteasomal balance, resulting in reduced proteasome activity. This reduction causes the accumulation of phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a key metabolic regulator, leading to enhanced neuronal glycolysis, reduced pentose phosphate pathway activity, oxidative injury, and ferroptosis. Neuron-specific genetic and systemic pharmacological targeting of PSMB8 or PFKFB3 protected neurons in vitro and in a mouse model of MS. Our findings provide a unifying explanation for proteasomal dysfunction in MS and possibly other neurodegenerative diseases, linking inflammation to metabolic disruption, and presenting an opportunity for targeted neuroprotective therapies.

28 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMark Walkenhorst
Mark Walkenhorst
JSJana K. Sonner
Jana K. Sonner
NMNina Meurs
Nina Meurs
JEJan Broder Engler
Jan Broder Engler
SBSimone Bauer
Simone Bauer
AWAnne Willing
Anne Willing
Mucosal-associated invariant T (MAIT) cells express semi-invariant T cell receptors (TCR) for recognizing bacterial and yeast antigens derived from riboflavin metabolites presented on the non-polymorphic MHC class I-related protein 1 (MR1). Neuroinflammation in multiple sclerosis (MS) is likely initiated by autoreactive T cells and perpetuated by infiltration of additional immune cells, but the precise role of MAIT cells in MS pathogenesis remains unknown. Here, we use experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, and find an accumulation of MAIT cells in the inflamed central nervous system (CNS) enriched for MAIT17 (RORγt+) and MAIT1/17 (T-bet+RORγt+) subsets with inflammatory and protective features. Results from transcriptome profiling and Nur77GFP reporter mice show that these CNS MAIT cells are activated via cytokines and TCR. Blocking TCR activation with an anti-MR1 antibody exacerbates EAE, whereas enhancing TCR activation with the cognate antigen, 5-(2-oxopropylideneamino)−6-D-ribitylaminouracil, ameliorates EAE severity, potentially via the induction of amphiregulin (AREG). In summary, our findings suggest that TCR-mediated MAIT cell activation is protective in CNS inflammation, likely involving an induction of AREG.

15 January 2026 in Nature Immunology
Verified
Journal Article
Open access
PDF file
JSJana K. Sonner
Jana K. Sonner
AKAudrey Kahn
Audrey Kahn
LBLars Binkle-Ladisch
Lars Binkle-Ladisch
JEJan Broder Engler
Jan Broder Engler
BHBeatrice Haack
Beatrice Haack
MFManuel A. Friese
Manuel A. Friese
Inflammatory activity during multiple sclerosis (MS) often improves during pregnancy, suggesting that pregnancy-related immune adaptations affect the disease. Here we show that growth/differentiation factor-15 (GDF-15) increases during pregnancy and correlates with a reduced rate of MS relapses. GDF-15 also accumulates in the inflamed central nervous system, and its absence impairs inflammation resolution in a mouse model of MS. GDF-15 suppresses autoimmune T cell responses through an indirect signaling pathway involving the activation of GDNF family receptor α-like (GFRAL) on brainstem neurons. Therapeutic approaches, including neuronal gene delivery, recombinant GDF-15 administration and targeted chemogenetic activation of GFRAL-positive neurons induce β-adrenergic signaling and norepinephrine synthesis in the spleen, leading to decreased expression of integrins on T cells required for transmigration across the blood–brain barrier and confer protection against neuroinflammation in preclinical models of MS. These findings position GDF-15 as a crucial neuroimmune mediator and the GDF-15–GFRAL axis as promising target for MS.

15 May 2024 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
IWIngo Winschel
Ingo Winschel
AWAnne Willing
Anne Willing
JEJan Broder Engler
Jan Broder Engler
MWMark Walkenhorst
Mark Walkenhorst
NMNina Meurs
Nina Meurs
MFManuel A. Friese
Manuel A. Friese
Background: Differences in immune responses between women and men are leading to a strong sex bias in the incidence of autoimmune diseases that predominantly affect women, such as multiple sclerosis (MS). MS manifests in more than twice as many women, making sex one of the most important risk factor. However, it is incompletely understood which genes contribute to sex differences in autoimmune incidence. To address that, we conducted a gene expression analysis in female and male human spleen and identified the transmembrane protein CD99 as one of the most significantly differentially expressed genes with marked increase in men. CD99 has been reported to participate in immune cell transmigration and T cell regulation, but sex-specific implications have not been comprehensively investigated. Methods: In this study, we conducted a gene expression analysis in female and male human spleen using the Genotype-Tissue Expression (GTEx) project dataset to identify differentially expressed genes between women and men. After successful validation on protein level of human immune cell subsets, we assessed hormonal regulation of CD99 as well as its implication on T cell regulation in primary human T cells and Jurkat T cells. In addition, we performed in vivo assays in wildtype mice and in Cd99-deficient mice to further analyze functional consequences of differential CD99 expression. Results: Here, we found higher CD99 gene expression in male human spleens compared to females and confirmed this expression difference on protein level on the surface of T cells and pDCs. Androgens are likely dispensable as the cause shown by in vitro assays and ex vivo analysis of trans men samples. In cerebrospinal fluid, CD99 was higher on T cells compared to blood. Of note, male MS patients had lower CD99 levels on CD4+ T cells in the CSF, unlike controls. By contrast, both sexes had similar CD99 expression in mice and Cd99-deficient mice showed equal susceptibility to experimental autoimmune encephalomyelitis compared to wildtypes. Functionally, CD99 increased upon human T cell activation and inhibited T cell proliferation after blockade. Accordingly, CD99-deficient Jurkat T cells showed decreased cell proliferation and cluster formation, rescued by CD99 reintroduction. Conclusions: Our results demonstrate that CD99 is sex-specifically regulated in healthy individuals and MS patients and that it is involved in T cell costimulation in humans but not in mice. CD99 could potentially contribute to MS incidence and susceptibility in a sex-specific manner.

7 May 2026 in EBioMedicine
Verified
Journal Article
Open access
MWMarcel S. Woo
Marcel S. Woo
NRNicola Rothammer
Nicola Rothammer
LBLukas C. Bal
Lukas C. Bal
CKChristoph Krisp
Christoph Krisp
MKMario Kreutzfeldt
Mario Kreutzfeldt
MFManuel A. Friese
Manuel A. Friese
Neuroaxonal and synaptic loss are hallmarks of multiple sclerosis (MS), the most common autoimmune disorder of the central nervous system. However, it remains unclear at which disease stages synaptic pathology occurs. We hypothesised that synaptic proteins in plasma and cerebrospinal fluid (CSF) reflect synaptic injury in MS. To identify synaptic proteins lost during neuroinflammation, we performed proteomic analysis of synaptoneurosomes from mice with experimental autoimmune encephalomyelitis (EAE), the model of MS. The findings were validated by histology in the cortex of EAE mice and postmortem MS tissue. Next, we developed an ELISA with knockout-validated antibodies for the presynaptic protein Bassoon (BSN) and quantified BSN in the cortex, spinal cords and plasma of EAE mice and in the CSF (total n = 30) and serum (total n = 146) of an observational cohort study with people with MS (pwMS) and controls. We further compared longitudinal trajectories of serum BSN (sBSN) and serum neurofilament light chain (sNfL) in a cohort of people with primary progressive MS (PPMS) (n = 26) using linear mixed-effects models. The synaptoneurosome screen revealed reduced levels of several presynaptic proteins, including BSN, in the cortex of EAE mice. The loss of synaptic BSN was validated in EAE and human postmortem tissues of pwMS. Notably, BSN simultaneously accumulated in neuronal soma during EAE and MS, suggesting that BSN may serve as a suitable biomarker for monitoring disease pathology. Our ELISA showed a gradual loss of BSN in the cortex of EAE mice and consistently, plasma BSN levels were elevated in two independent acute and chronic EAE cohorts. In pwMS, BSN was detectable in all CSF samples and in 81% of the serum samples. CSF BSN levels were higher in both relapsing and PPMS compared with controls, whereas sBSN was elevated in secondary progressive MS (SPMS) and PPMS. In the longitudinal PPMS cohort, sBSN and sNfL remained unchanged over an average follow-up of 37 months and did not correlate with each other. In conclusion, the presynaptic protein BSN can be quantified in plasma and CSF to assess synaptic pathologies. BSN elevation was already detectable at the earliest disease stages and persisted in progressive MS, underscoring continuous neurodegeneration in MS. Measuring synaptic proteins may complement established biomarkers of neuronal injury to enhance our understanding of neurodegeneration in MS. This work was funded by the Hamburg Innovation Call for Transfer (C4T959 to M.A.F.), Deutschen Multiple Sklerose Gesellschaft (V6.2 to M.A.F.). This work is supported by the Deutsche Forschungsgemeinschaft (FOR 5705, 523862973 to M.A.F., S.C.R., J.B.E.; 247354600, 247377969, 426788273, 518551069, 516868494 to H.S.).